NEW YORK (GenomeWeb News) – Shares of Pacific Biosciences climbed 12 percent in Friday afternoon trade after regulatory documents filed Thursday showed that Mike Hunkapiller, the firm's chairman, president, and CEO, had purchased 200,000 shares of the firm's stock on the open market.

According to a Form 4 filed with the US Securities and Exchange Commission, Hunkapiller bought the shares in multiple transactions at prices ranging from $3.51 to $3.72 and at an average price of $3.61 per share. Hunkapiller now owns 1.7 million shares of the firm's stock, according to the filing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.